Kura Oncology Inc (NASDAQ: KURA) flaunted slowness of -4.81% at $8.91, as the Stock market unbolted on Thursday, before settling in for the price of $9.36 at the close. Taking a more long-term approach, KURA posted a 52-week range of $5.41-$12.49.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -6.05%. Meanwhile, its Annual Earning per share during the time was -6.05%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -30.66%. This publicly-traded company’s shares outstanding now amounts to $87.02 million, simultaneously with a float of $84.15 million. The organization now has a market capitalization sitting at $775.32 million.
Kura Oncology Inc (KURA) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Kura Oncology Inc industry. Kura Oncology Inc’s current insider ownership accounts for 3.29%, in contrast to 96.10% institutional ownership. According to the most recent insider trade that took place on Dec 18 ’25, this organization’s Chief Scientific Officer sold 23,726 shares at the rate of 9.78, making the entire transaction reach 231,931 in total value, affecting insider ownership by 33,735.
Kura Oncology Inc (KURA) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.89 per share during the current fiscal year.
Kura Oncology Inc’s EPS decrease for this current 12-month fiscal period is -30.66% and is forecasted to reach -2.66 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -5.92% through the next 5 years, which can be compared against the -6.05% growth it accomplished over the previous five years trading on the market.
Kura Oncology Inc (NASDAQ: KURA) Trading Performance Indicators
Let’s observe the current performance indicators for Kura Oncology Inc (KURA). It’s Quick Ratio in the last reported quarter now stands at 5.12. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 7.45. Similarly, its price to free cash flow for trailing twelve months is now 9.33.
In the same vein, KURA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.48, a figure that is expected to reach -0.41 in the next quarter, and analysts are predicting that it will be -2.66 at the market close of one year from today.
